Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
FRAMINGHAM, MA / ACCESSWIRE / September 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.
馬薩諸塞州弗雷明翰/ACCESSWIRE/2022年9月7日亞洲網加利福尼亞州聖克拉拉9月23日電致力於推進用於治療難治性癌症的創新免疫腫瘤學技術的生物製藥公司Xenetic Biosciences，Inc.(納斯達克代碼：XBIO)(以下簡稱“Xenetic”或“公司”)今天宣佈，Xenetic首席執行官傑弗裏·F·艾森伯格將出席2022年9月12-14日在紐約舉行的H.C.Wainwright第24屆全球投資年會。
In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.
除了介紹外，管理層還可以參加虛擬的一對一會議，與註冊參加會議的投資者羣體中合格的成員舉行會議。欲瞭解更多信息，請訪問大會網站。
A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 12 at 7:00 AM ET for those registered for the event and will be available on the Events page in the Investors section of the Company's website (). The webcast replay will be archived for 90 days following the event.
9月12日(星期一)美國東部時間上午7：00起，已註冊參加活動的人員可通過視頻網絡直播觀看演示文稿，並可在公司網站投資者部分的活動頁面上觀看()。網絡直播重播將在活動結束後90天內存檔。
About Xenetic Biosciences
關於遺傳生物科學
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Xenetic Biosciences，Inc.是一家生物製藥公司，專注於推進創新的免疫腫瘤學技術，以解決難以治療的癌症。該公司的DNase平臺旨在通過瞄準與癌症進展有關的中性粒細胞外陷阱(Net)來改善包括免疫療法在內的現有治療的結果。Xenetic目前專注於將其全身性DNA ase計劃推向臨牀，作為胰腺癌和局部晚期或轉移性實體腫瘤的輔助治療。
The Company is also developing its personalized CAR T platform technology, XCARTT, to develop cell-based therapeutics targeting the unique B-Cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-Cell lymphomas.
該公司還在開發其個性化CAR T平臺技術XCARTT，以開發針對單個患者惡性腫瘤細胞表面獨特的B細胞受體的基於細胞的療法，用於治療B細胞淋巴瘤。
For more information, please visit the Company's website at and connect on Twitter, LinkedIn, and Facebook.
欲瞭解更多信息，請訪問公司網站，並連接Twitter、LinkedIn和Facebook。
CONTACT:
聯繫方式：
JTC Team, LLC
JTC團隊，有限責任公司
Jenene Thomas
珍妮·託馬斯
(833) 475-8247
(833) 475-8247
xbio@jtcir.com
郵箱：xbio@jtCir.com
SOURCE: Xenetic Biosciences, Inc.
資料來源：Xenetic生物科學公司。
View source version on accesswire.com:
在accesswire.com上查看源代碼版本：
COMTEX_413919573/2457/2022-09-07T08:05:37
COMETX_413919573/2457/2022-09-07T08：05：37